Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Razmig Haladjian

Interventional Pain Medicine Brownstown, MI Medical Doctor

NPI 1750335188 CMS profile 261399

19725 Allen Rd, Suite A, Brownstown, MI 48183

Open in the dashboard

General payments

$16,882

615 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$69,675 paid to institutions, not to them · program years 2019–2024

Through program year 2025, Razmig Haladjian of Brownstown, MI is reported in the CMS Open Payments database as having received $16,882 across 615 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $69,675 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 83rd percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,526 59
2024 General $1,615 50
2023 General $2,409 84
2022 General $2,032 81
2021 General $4,128 101
2020 General $1,546 87
2019 General $3,626 153

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Razmig Haladjian
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Razmig Haladjian were reported at $1,526. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Razmig Haladjian Interventional Pain Medicine median Middle half National median
2019 $3,626 $684 $216–$2,079 $163
2020 $1,546 $382 $122–$1,109 $114
2021 $4,128 $552 $167–$1,554 $132
2022 $2,032 $605 $187–$1,924 $149
2023 $2,409 $671 $195–$1,915 $160
2024 $1,615 $684 $206–$1,837 $164
2025 $1,526 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $2,988 18 payments
  2. Nevro Corp. $2,073 64 payments
  3. Vertos Medical, Inc. $1,368 35 payments
  4. Relievant Medsystems, Inc. $1,104 11 payments
  5. AbbVie, Inc. $965 54 payments
  6. Medtronic USA, Inc. $832 30 payments
  7. Boston Scientific Corporation $687 31 payments
  8. Scilex Pharmaceuticals Inc. $669 38 payments
  9. Amgen Inc. $469 34 payments
  10. Collegium Pharmaceutical, Inc. $466 26 payments
  11. Other $5,260 274 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $13,535 611 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $2,500 1 payment
  3. Travel and Lodging $848 3 payments
Products named General payments · program years 2019–2025
  1. RESTORE $2,500 1 payment
  2. Senza $1,286 32 payments
  3. Intracept $876 6 payments
  4. mild Device Kit Orthopedic $801 23 payments
  5. Omnia $717 27 payments
  6. INTELLIS $714 28 payments
  7. mild Device Kit Orthopedic $567 12 payments
  8. ZTLido $470 25 payments
  9. PNS FREEDOM-4A PERMANENT NEUROSTIMULATOR RECEIVER KIT CHANNEL A $450 5 payments
  10. BOTOX $450 30 payments
  11. Other $9,742 535 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 31 drugs

Part D claims

2,493

Median for Anesthesiology: 322

Drug cost

$86,971

Median for Anesthesiology: $8,738

Branded share of claims

45%

Median for Anesthesiology: 25.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Diclofenac Sodium Generic 38 $14,941
Belbuca Buprenorphine Hcl Brand 32 $13,266
Movantik Naloxegol Oxalate Brand 28 $11,940
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 654 $9,223
Buprenorphine Generic 24 $5,073
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 311 $4,916
Pregabalin Generic 180 $4,874
Gabapentin Generic 265 $4,133
Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl Brand 31 $3,972
Lidocaine Generic 43 $3,503

The 10 drugs with the highest cost, of 31 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,517 Part D prescribers listed as Anesthesiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 51 billing codes

Paid by Medicare

$342,478

Of which drugs: $1,329

Medicare patients

616

Average age 69

Services billed

13,765

398 women, 218 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 38%
Depression 33%
Ischemic heart disease 32%
COPD 31%
Chronic kidney disease 28%
Heart failure 22%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 90 10,372 $1,047
Injection, methylprednisolone acetate, 80 mg J1040 Office 26 28 $201
Injection, methylprednisolone acetate, 40 mg J1030 Office 14 16 $81

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BOTOX
  • AbbVie, Inc. $79
$79 — —
ZTLido
  • Scilex Pharmaceuticals Inc. $70
$70 — —
UBRELVY
  • AbbVie, Inc. $48
$48 — —
NURTEC ODT
  • PFIZER INC. $44
$44 — —
ZAVZPRET
  • PFIZER INC. $44
$44 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

615 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record